Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04997057

A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation — EPORE  

Irritable Bowel Syndrome With Constipation Clinical Trial

Official title:
Effect of a Mixture of Probiotics (Lactibiane Reference) in Patients With Irritable Bowel Syndrome Predominantly Constipation and Assessment of a Potential Biomarker (Resolvin D1): an Exploratory Study

Clinical Trial Summary

Probiotics efficacy is mainly assessed by subjective endpoints such as the FDA responder rate or global relief, which partly explain contradictory results obtained in clinical trials with probiotic bacteria. Objective biomarkers of IBS will allow to measure the efficacy of probiotics. In the case of IBS-C, serum resolvin-D1 appears to be an interesting candidate due to its non-invasive and discriminating character compared to a healthy population. It is, inversely correlated with the severity of symptoms. Resolvin-D1 modulates the duration and intensity of inflammation by regulating the transcription of cytokines, chemokines and their receptors as well as other proteins involved in inflammation. Resolvin D1 could serve as a predictor of probiotic response based on its baseline value.

Clinical Trial Description

Resolvin D1 levels will be measured in patients with IBS-C as defined by the Rome IV criteria before 6 and 12 weeks after supplementation with a mixture of probiotics. The progression of IBS-C symptoms will also be assessed throughout the study. The correlation with resolvin D1 levels and the severity of IBS symptoms will be investigated. The efficacy of the probiotic mixture in relieving the symptoms of IBS-C will be measured and compared based on the levels of resolvin D1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04997057
Study type Interventional
Source CEN Biotech
Contact
Status Completed
Phase N/A
Start date January 4, 2022
Completion date December 9, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00215566 - A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c Phase 2
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT02559206 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Recruiting NCT05646186 - Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Recruiting NCT05519683 - Home Transcutaneous Electrical Acustimulation (TEA) Phase 2/Phase 3
Active, not recruiting NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3
Completed NCT04968652 - IBS-C Questionnaire Study
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Terminated NCT02559817 - A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation Phase 2
Recruiting NCT05796388 - A Study of Virtual Reality and Linaclotide for IBS-C N/A
Completed NCT00380250 - Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT04647045 - An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant N/A
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Not yet recruiting NCT06219707 - Electro-acupuncture for Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Completed NCT04132804 - Effect of Tai Chi as Treatment for IBS-C N/A